News
-
-
-
PRESS RELEASE
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva's public tender offer. Offer price of EUR 10.00 per share represents a premium. Acceptance period ends on 21 November 2024 -
-
-
-
-
-
PRESS RELEASE
APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer
APONTIS PHARMA partners with Zentiva for growth, offering shareholders EUR 10.00 per share in a voluntary public purchase offer. Zentiva aims for majority stake and strategic collaboration -
PRESS RELEASE
EQS-Adhoc: APONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offer
APONTIS PHARMA and Zentiva enter into investment agreement for voluntary public purchase offer at EUR 10.00 per share in cash. Zentiva aims to support future growth of APONTIS PHARMA
